Detailed Information on Publication Record
2022
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma
MOEHLER, Markus, Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ, Maria ALSINA et. al.Basic information
Original name
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma
Authors
MOEHLER, Markus (guarantor), Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), Maria ALSINA, Peter THUSS-PATIENCE, van Laarhoven HANNEKE and Elizabeth SMYTH
Edition
European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 8.400
RIV identification code
RIV/00216224:14110/22:00128423
Organization unit
Faculty of Medicine
UT WoS
000892112500002
Keywords in English
Checkpoint inhibitors; Esophageal cancer; Esophagogastric cancer; Her2-positive; Immunotherapy; Gastric cancer; PD-L1; PD-1
Tags
International impact, Reviewed
Změněno: 31/1/2023 09:19, Mgr. Tereza Miškechová
Abstract
V originále
The new era of immunotherapy is successfully implemented in the treatment of metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been investi-gated in combinations with/without chemotherapy in human epidermal growth factor receptor 2 (Her2)-positive and Her2-negative tumors. Recent approvals of immune checkpoint inhibi-tors (ICI) enrich the therapeutic landscape in nearly every therapeutic line. Based on CHECKMATE-649, the combination of nivolumab and chemotherapy in first-line therapy of programmed cell death protein 1 (PD-L1)-positive patients with advanced gastroesophageal junction cancer (GEJC), esophageal cancer (EC), and gastric cancer (GC) was approved in Europe for PD-L1 combined positivity score (CPS) >= 5 patients and independently from PD-L1 score in the USA and Asia. Based on KEYNOTE-590, patients with advanced GEJC and EC qualify for the combination of pembrolizumab plus chemotherapy in Europe (CPS > 10) and the USA. For Her2-positive patients, trastuzumab with first-line chemo-therapy plus pembrolizumab has beneficial response rates and resulted in approval in the USA (KEYNOTE-811). In third-line therapy, superior overall survival (OS) was achieved by the administration of nivolumab (approval in Japan, ATTRACTION-02), and pembroli-zumab shows a positive effect on the duration of response (KEYNOTE-059). Questions of resistance to immunotherapy or the role of gender in response to ICI need to be clarified. This review provides an overview of the current approvals of ICI in advanced EGAC and reflects results of relevant phase II/III trials with focus on possible biomarkers, including PD-L1 CPS and microsatellite-instability (MSI) status.